ArticleLiver cancer2020

Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.

Angel Alsina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.